<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04641312</url>
  </required_header>
  <id_info>
    <org_study_id>17261</org_study_id>
    <secondary_id>2020-001828-34</secondary_id>
    <secondary_id>J1R-MC-GZFA</secondary_id>
    <nct_id>NCT04641312</nct_id>
  </id_info>
  <brief_title>A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes</brief_title>
  <official_title>A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 in Healthy Participants and in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to investigate the safety and tolerability of the study&#xD;
      drug LY3457263 in healthy participants and participants with type 2 diabetes. Blood tests&#xD;
      will be performed to investigate how the body processes the study drug and how the study drug&#xD;
      affects the body. The study has two parts (part A and B). Each part will last up to 10 weeks&#xD;
      and may include up to either 13 (part A) or 19 (part B) visits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 25, 2020</start_date>
  <completion_date type="Anticipated">December 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Day 42</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3457263</measure>
    <time_frame>Day 1 through Day 42</time_frame>
    <description>PK: AUC[0-inf] of LY3457263</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Healthy</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>LY3457263 - Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating single doses of LY3457263 administered subcutaneously (SC) to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Part A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3457263 - Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating single doses of LY3457263 administered SC in combination with Dulaglutide administered SC to participants with type 2 diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Part B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC in combination with Dulaglutide administered SC to participants with type 2 diabetes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3457263</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3457263 - Part A</arm_group_label>
    <arm_group_label>LY3457263 - Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3457263 - Part B</arm_group_label>
    <arm_group_label>Placebo - Part B</arm_group_label>
    <other_name>LY2189265</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo - Part A</arm_group_label>
    <arm_group_label>Placebo - Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males that agree to use an effective method of contraception or agree to remain&#xD;
             abstinent&#xD;
&#xD;
          -  Females that are not of childbearing potential due to postmenopausal status or due to&#xD;
             surgical sterility&#xD;
&#xD;
          -  Part A only:&#xD;
&#xD;
               -  Are overtly healthy&#xD;
&#xD;
               -  Body mass index (BMI) of 18.5 to 35 kilograms per meter squared (kg/m²)&#xD;
&#xD;
          -  Part B only:&#xD;
&#xD;
               -  Have been diagnosed with Type 2 Diabetes (T2D) for at least 6 months prior to&#xD;
                  screening&#xD;
&#xD;
               -  Be treated for T2D with stable dose of metformin, a stable dose of a dipeptidyl&#xD;
                  peptidase-4 (DPP-4) inhibitor with or without metformin, or a stable dose of a&#xD;
                  glucagon-like peptide-1 (GLP-1) receptor agonist with or without metformin for at&#xD;
                  least 3 months prior to screening&#xD;
&#xD;
               -  BMI of 27 to 40 kg/m²&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have undergone any form of bariatric surgery&#xD;
&#xD;
               -  Have used or intend to use medications that promote weight loss within 3 months&#xD;
                  prior to screening, for the duration of the study&#xD;
&#xD;
               -  Part A only:&#xD;
&#xD;
                    -  Have fasting plasma glucose (PG) levels ≥7 millimoles per liter (mmol/L)&#xD;
                       (≥126 milligrams per deciliter (mg/dL)) at screening&#xD;
&#xD;
                    -  Have Hemoglobin A1c (HbA1c) level ≥ 6.5% (48 millimoles per mole (mmol/mol))&#xD;
                       at screening&#xD;
&#xD;
                    -  Have serum aspartate aminotransferase (AST) or alanine aminotransferase&#xD;
                       (ALT) &gt;20% and 10%, above the upper limit of normal (ULN), respectively.&#xD;
                       Elevation of total bilirubin level is considered acceptable in case of&#xD;
                       Gilbert's disease (with a normal direct bilirubin)&#xD;
&#xD;
               -  Part B only:&#xD;
&#xD;
                    -  Have Type 1 Diabetes or latent autoimmune diabetes in adults&#xD;
&#xD;
                    -  Have uncontrolled diabetes defined as an episode of ketoacidosis or&#xD;
                       hyperosmolar state requiring hospitalization in the 6 months prior to&#xD;
                       screening&#xD;
&#xD;
                    -  Have known proliferative diabetic retinopathy, diabetic maculopathy, or&#xD;
                       severe nonproliferative diabetic retinopathy&#xD;
&#xD;
                    -  Present comorbid conditions commonly associated with diabetes (for example,&#xD;
                       hypertension, hypercholesterolemia, hypothyroidism) unless they are&#xD;
                       well-controlled with stable medication&#xD;
&#xD;
                    -  Have had an episode of severe hypoglycaemia within 6 months prior to&#xD;
                       screening, or have a history of hypoglycaemia unawareness or poor&#xD;
                       recognition of hypoglycaemia&#xD;
&#xD;
                    -  Have a history of acute or chronic pancreatitis or elevation in serum lipase&#xD;
                       and/or amylase &gt;2 × ULN at screening&#xD;
&#xD;
                    -  Have a resting heart rate of &lt;50 or &gt;100 beats per minute&#xD;
&#xD;
                    -  Have an estimated glomerular filtration rate (&lt;60 milliliter/minute&#xD;
                       (mL/min)/1.73 m2, or a level of estimated glomerular filtration rate that&#xD;
                       would contraindicate the use of metformin per the label in the respective&#xD;
                       country&#xD;
&#xD;
                    -  Have a screening calcitonin ≥20.0 picograms per milliliter (pg/mL)&#xD;
&#xD;
                    -  Fasting serum triglyceride level of &gt;500 mg/dL at screening&#xD;
&#xD;
                    -  Have serum AST or ALT &gt;3 × ULN or TBL &gt;1.5 × ULN (except for participants&#xD;
                       diagnosed with Gilbert's syndrome)&#xD;
&#xD;
                    -  Have taken any prescription medication that are specifically indicated for&#xD;
                       lowering serum triglycerides within the last 3 months&#xD;
&#xD;
                    -  Have taken within the last 3 months any medications that interfere with&#xD;
                       absorption of dietary cholesterol or fats&#xD;
&#xD;
                    -  Use of medications known to prolong the QT/QTc interval&#xD;
&#xD;
                    -  Treated only with diet and exercise at study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung</name>
      <address>
        <city>Neuss</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Profil Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 15, 2021</verification_date>
  <study_first_submitted>November 20, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

